Exclusive U.S. licensing deal aims to reshape colorectal cancer screening landscape Exact Sciences secured exclusive U.S. commercialization rights to Freenome’s blood-based colorectal cancer screening test
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
Vepdegestrant PROTAC estrogen receptor degrader targets ER+ breast cancer with novel mechanism The FDA accepted Arvinas and Pfizer’s New Drug Application for vepdegestrant (ARV-471), granting
Melanoma vaccine combination shows numerical benefit but misses primary endpoint, shares plummet 34% IO Biotech’s Phase 3 trial evaluating its IO102/IO103 therapeutic cancer vaccine (Cylembio)
Thermo Fisher’s companion diagnostic enables precision treatment with zongertinib for rare NSCLC subset The FDA approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a
French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
Strategic deal adds premium implantable lens technology at 51% premium to strengthen refractive surgery position Alcon announced its agreement to acquire STAAR Surgical for approximately
PharmaTher’s KETARx becomes first FDA-approved ketamine formulation for on-label surgical use In a historic regulatory milestone, the FDA approved PharmaTher’s KETARx on August 8, 2025,
Phase 3 trial demonstrates practice-changing survival benefits in muscle-invasive disease Pfizer announced highly positive interim results from a pivotal Phase 3 trial combining its antibody-drug
Major intellectual property resolution clears path for both companies’ mRNA pipelines GlaxoSmithKline reached a landmark settlement in its high-stakes mRNA vaccine intellectual property litigation with
